Please login to the form below
melanoma
This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
Roche’s Tecentriq combo scores FDA approval for melanoma
Tecentriq, plus MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelboraf (vemurafenib), has been backed for the treatment of BRAF V600 mutation-positive advanced melanoma patients. ... The FDA approval of this Tecentriq combination represents an
Latest news
-
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
In addition to lung cancer, Merck’s drug is approved for a host of other cancer types, including in China for advanced melanoma.
-
Newly-listed BioNTech buys Neon to boost cell therapy assets
The lead drug in that programme is NEO-PTC-01, a T-cell therapy targeting shares RAS oncogenes in solid tumours, initially heading for a clinical trial on metastatic melanoma patients
-
Lilly ends $1.4bn deal with immuno-oncology biotech NextCure
The trial included patients with non-small cell lung cancer, ovarian cancer, melanoma, breast cancer and colorectal cancer and all were heavily pre-treated with a median of three prior therapies.
-
Nektar’s opioid analgesic slammed with FDA panel rejection
This includes studies, either underway or planned, in small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer, sarcoma, melanoma, renal cell carcinoma, bladder cancer and
-
BMS expands collaboration with Nektar, sending shares soaring
Currently, the partners are testing bempeg and Opdivo in three ongoing registrational trials in first-line metastatic melanoma, first-line chemotherapy-ineligible metastatic urothelial cancer and first-line metastatic renal cell ... carcinoma. The
More from news
Approximately 82 fully matching, plus 289 partially matching documents found.
Latest Intelligence
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute.
-
Immuno-oncology in 2019: the rapid evolution continues
BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as
-
Is China ready for a pharmaceutical gold rush?
China’s millions of tobacco smokers make for a large market, which may be why BMS filed for approval in lung cancer treatment, rather than melanoma, the leading indication in other
-
Combined immunotherapies – potential and pitfalls
The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.
-
Cancer immunotherapy: What's on the horizon?
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.
More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.
Latest appointments
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
Bruno Strigini leaves Merck & Co for Novartis
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
-
Chris Bowden joins Agios
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
If our patients are diverse, why are clinical trials so white?
According to the largest study (to date) in different racial and ethnic populations across the US, there was no evidence to support the association of UV exposure and melanoma incidence in ... black or Hispanic populations – studies assessing the
-
Lucid Group expands its presence in the north-west with six new hires
and the response of uveal melanoma.
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Manufacturer. Indication. Notes. Nivolumab. Opdivo. Bristol-Myers Squibb. Front-line monotherapy in patients with unresectable and metastatic melanoma.
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
In its earlier phase 1 monotherapy trial, TAVO demonstrated a 46% response rate in untreated lesions in metastatic melanoma. ... Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to
-
Artificial Intelligence in healthcare
It missed fewer melanomas, meaning it had a higher sensitivity, and it misdiagnosed fewer benign moles as malignant melanoma, meaning it also had a higher specificity.[15]. ... Man against machine: diagnostic performance of a deep learning convolutional
More from PMHub
Approximately 1 fully matching, plus 13 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- Gut instincts lead Takeda to GI pipeline success
- How will the events and exhibitions industry change post-Coronavirus?
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Roche’s Tecentriq combo scores FDA approval for melanoma
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
- Virtual Reality in Medicine and Clinical Research
- J&J inks $1bn deal with US for coronavirus vaccine
- Novartis builds its case for novel MS treatment ofatumumab
- Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
